AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Investor Presentation (February 2019)

34 slides from AVEO Pharmaceuticals's investor presentation, Feb 15, 2019

  1. Slide 1: AVEO Overview February 2019

    Slide 1: AVEO Overview February 2019

    AVEO Overview February 2019 Exhibit 99.1

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate

  3. Slide 3: AVEO Oncology: Strategy for Value Creation

    Slide 3: AVEO Oncology: Strategy for Value Creation

    AVEO Oncology: Strategy for Value Creation Deep Pipeline Multiple oncology and non-oncology pipeline opportunities Meaningful Market Opportunity Better tolerated single agents/combinations are the next stage of evolution Three Pillar Clinical & Regulatory Strategy EU approved, US NDA plan, IO combin

  4. Slide 4: Multiple Potential Opportunities for Value Creation

    Slide 4: Multiple Potential Opportunities for Value Creation

    Multiple Potential Opportunities for Value Creation Oncology Preclinical Phase 1 Phase 2 Phase 3 Regulatory Filing Marketed Partner Tivozanib VEGFR 123 TKI Ficlatuzumab HGF MAb AV-203 (CAN017) ERBB3 MAb TIVO-1 (Phase 3 Registration Study in 1st Line RCC) TIVO-3 (Phase 3 Registration Study in 3rd Lin

  5. Slide 5: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor

    Slide 5: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor

    Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1 Nakamura K et al. Cancer Res 2006;66:9134–9142. 2 Eskens FA et al. Clin Cancer Res 2011;17:71

  6. Slide 6: FOTIVDA (tivozanib) TIVO-3 Pivotal Phase Study

    Slide 6: FOTIVDA (tivozanib) TIVO-3 Pivotal Phase Study

    FOTIVDA® (tivozanib) TIVO-3 Pivotal Phase 3 Study

  7. Slide 7: TIVO-3: Study Design

    Slide 7: TIVO-3: Study Design

    TIVO-3: Study Design N = 350 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI Stratified by prior regimen (TKI-TKI; TKI-PD1; TKI-Other) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and Tolerability for ITT 60% 3rd line patients, 4

  8. Slide 8: Primary Endpoint: Progression-Free Survival per IRC (ITT)

    Slide 8: Primary Endpoint: Progression-Free Survival per IRC (ITT)

    Primary Endpoint: Progression-Free Survival per IRC (ITT) Median PFS, mo (95% CI) Tivozanib 5.6 (5.3, 7.3) Sorafenib 3.9 (3.7, 5.6) HR, 0.73 (95% CI: 0.56, 0.94) P=0.0165 2yr PFS 18% 5% 28% 1yr PFS 11% 44% improvement in median PFS 26% risk reduction for progression or death

  9. Slide 9: Subgroup Progression-Free Survival per IRC (Prior IO Subgroup)

    Slide 9: Subgroup Progression-Free Survival per IRC (Prior IO Subgroup)

    Subgroup Progression-Free Survival per IRC (Prior IO Subgroup - 26% of ITT) Median PFS, mo (95% CI) Tivozanib 7.3 (5.3, 11.1) Sorafenib 5.1 (3.6, 7.4) HR, 0.55 (95% CI: 0.32, 0.94) P=0.028 35% 1yr PFS 4% 2yr PFS 25% 43% improvement in median PFS 45% risk reduction for progression or death

  10. Slide 10: Secondary Endpoints

    Slide 10: Secondary Endpoints

    Secondary Endpoints Preliminary analysis (HR=1.12) represents approx. half of potential OS events 43 patients remain on study therapy (34 tivozanib vs 9 sorafenib) Interim OS analysis: Planned for August 2019 Preliminary Analysis - OS Not Mature at Time of Final PFS Analysis Final Analysis - Superio

  11. Slide 11: Treatment-Related Adverse Events

    Slide 11: Treatment-Related Adverse Events

    Treatment-Related Adverse Events (≥20% frequency in either arm) Tivozanib (N=173)^ Sorafenib (N=170)^ Preferred Term, % All Grades Grade 3/4 All Grades Grade 3/4 Treatment Related AEs 84 44 94 55 Hypertension 36 20 25 14 Diarrhea 33 2 50 9 Fatigue 29 4 19 5 Decreased Appetite 26 4 21 2 Dysphonia 24

  12. Slide 12: The Conundrum: What Is Causing the PFS/OS Discordance?

    Slide 12: The Conundrum: What Is Causing the PFS/OS Discordance?

    The Conundrum: What Is Causing the PFS/OS Discordance? Is there a safety issue with tivozanib? Is there an imbalance in the study? Are the preliminary OS data too immature to reflect potential long term differences? Final PFS Preliminary OS

  13. Slide 13: Is There a Safety Issue with Tivozanib?

    Slide 13: Is There a Safety Issue with Tivozanib?

    Is There a Safety Issue with Tivozanib?

  14. Slide 14: Safety and Exposure Data: No Apparent Safety Signal

    Slide 14: Safety and Exposure Data: No Apparent Safety Signal

    Tivozanib (N=173)^ Sorafenib (N=170)^ Mean Number of Cycles Initiated 10.3 6.3 AEs Leading to Dose Reductions, % 24 38 AEs Leading to Dose Interruption, % 48 63 Treatment Related SAEs, % 11 10 Treatment Related Deaths, % 0 0 Deaths within 30 days of Tx, N 15 12 Exposure Adj Deaths per Month of Tx* 0

  15. Slide 15: Extended Exposure to Tivozanib Does Not Appear to Adversely Impact OS

    Slide 15: Extended Exposure to Tivozanib Does Not Appear to Adversely Impact OS

    Data Demonstrate That Extended Exposure to Tivozanib Does not Appear to Adversely Impact OS Tivozanib correlation (R2=0.6) relative to sorafenib (R2=0.2), suggests that increased exposure to tivozanib may be more associated with OS benefit

  16. Slide 16: Is There an Imbalance in the Study?

    Slide 16: Is There an Imbalance in the Study?

    Is There an Imbalance in the Study?

  17. Slide 17: Preliminary Subsequent Therapy Rates and CPI Therapy Higher for Sorafenib

    Slide 17: Preliminary Subsequent Therapy Rates and CPI Therapy Higher for Sorafenib

    Preliminary Subsequent Therapy Rates and CPI Therapy Higher for Sorafenib: Potential to Balance Over Time Treatment, N (%) Tivozanib (N=175) Sorafenib (N=175) Remain on Study Treatment* 34 (19) 9 (5) Unknown Subsequent Therapy 37 (27) 64 (37) No Subsequent Therapy 23 (13) 20 (11) Any Subsequent Ther

  18. Slide 18: Are the OS Data Too Immature?

    Slide 18: Are the OS Data Too Immature?

    Are the OS Data Too Immature?

  19. Slide 19: Preliminary OS Analysis Enriched with Patients with Minimal PFS Benefit

    Slide 19: Preliminary OS Analysis Enriched with Patients with Minimal PFS Benefit

    Preliminary OS Analysis is Enriched with Patients Who Realized Minimal PFS Benefit 2yr PFS 18% 5% 28% 1yr PFS 11% TIVO-3 PFS Curve (ITT) 72% of OS events in preliminary analysis from patients with <4 months of PFS

  20. Slide 20: TIVO-3 Conclusions

    Slide 20: TIVO-3 Conclusions

    TIVO-3 Conclusions Tivozanib significantly improves PFS and ORR compared to sorafenib in patients with treatment-refractory advanced RCC Tivozanib was superior in patients previously treated with checkpoint inhibitors as well as two VEGFR-TKIs Responses with tivozanib were more durable than sorafeni

  21. Slide 21: Significant Potential Commercial Opportunity for Tivozanib in the United States

    Slide 21: Significant Potential Commercial Opportunity for Tivozanib in the United States

    If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States 1st Line Market ~$1.3B1 2nd Line Market ~$900M1 3rd Line+ Market ~$300M1 Expanding opportunity Potential to be first agent indicated for 3rd & 4th line Only pivotal dataset in RCC stratified by prior PD-1 NA

  22. Slide 22: Potential Relevance of Tivozanib in Refractory RCC

    Slide 22: Potential Relevance of Tivozanib in Refractory RCC

    Potential Relevance of Tivozanib in Refractory RCC Source: AVEO blinded US Oncologist Market Research using approximate TIVO-3 PFS and AE profile - Dec 2018 n=100 Treatments with proven efficacy are needed for patients who have failed 2 or more lines of treatment for RCC I prefer using drugs that do

  23. Slide 23: PD-1 Combination Opportunities

    Slide 23: PD-1 Combination Opportunities

    PD-1 Combination Opportunities

  24. Slide 24: Tivozanib High Selectivity May Be a Significant Advantage

    Slide 24: Tivozanib High Selectivity May Be a Significant Advantage

    Tivozanib High Selectivity1 May Be a Significant Advantage ASCO 2017 – GU Oral Discussion2 Confidential 1 Nakamura K et al. Cancer Res 2006;66:9134–9142. 2 Hammers, Emerging VEGF-I/O Combinations: Efficacy and Toxicity, ASCO 2017

  25. Slide 25: Tivozanib Immunomodulatory Properties: Regulatory T Cell Reduction

    Slide 25: Tivozanib Immunomodulatory Properties: Regulatory T Cell Reduction

    Tivozanib has Immunomodulatory Properties: Regulatory T Cell Reduction May Enhance PD-1 Activity Pawlowski N et al. AACR 2013. Poster 3971. Regulatory T cells suppress or downregulate induction and proliferation of effector T cells (e.g. CD4 and CD8) P=0.034

  26. Slide 26: Demonstrated Favorable Safety

    Slide 26: Demonstrated Favorable Safety

    Demonstrated Favorable Safety 60% of patients experienced treatment related grade 3/4 adverse event Excluding uncomplicated hypertension, only 44% of patients experienced grade 3/4 adverse event Minimal off-target AEs observed, likely due to high specificity of tivozanib Barthelemy et al. ESMO 2018

  27. Slide 27: Demonstrated Encouraging Preliminary Efficacy

    Slide 27: Demonstrated Encouraging Preliminary Efficacy

    Demonstrated Encouraging Preliminary Efficacy 56% ORR and 96% DCR 72% had tumor shrinkage ≥25% so far 4% of patients had a complete response 52% (13/25) of pts remain on therapy Results suggest additive or synergistic efficacy for tivozanib + PD1 Barthelemy et al. ESMO 2018

  28. Slide 28: Preliminary Data for the Combination of PD-1 + VEGF TKIs

    Slide 28: Preliminary Data for the Combination of PD-1 + VEGF TKIs

    Preliminary Data for the Combination of PD-1 + VEGF TKIs: Promising Responses with Challenging Toxicity Safety (%) Tivozanib + Nivolumab1 Total N=25 Pembro + Lenvatinib4 Total N=30 Cabo^ + Nivo or IpiNivo5 GU Tumors Total N=78 (49-CN; 29-CNI) Axitinib + Pembro2 Total N=52 Axitinib + Avelumab3 Total

  29. Slide 29: Immuno-Oncology Clinical Collaboration with AstraZeneca

    Slide 29: Immuno-Oncology Clinical Collaboration with AstraZeneca

    Immuno-Oncology Clinical Collaboration with AstraZeneca Clinical Rationale: Potential to show enhanced efficacy and best in class tolerability profile for a TKI/IO combination with tivozanib and durvalumab Planned Ph1/2 study: costs shared equally and clinical drug supplied by each company HCC Marke

  30. Slide 30: Partnerships, Pipeline and Financials Highlights

    Slide 30: Partnerships, Pipeline and Financials Highlights

    Partnerships, Pipeline and Financials Highlights

  31. Slide 31: EUSA Partnership: European Launch and Milestones

    Slide 31: EUSA Partnership: European Launch and Milestones

    Decision Resources Pharmacor Market Projections Dec 2017 https://www.onkopedia.com/de/onkopedia/guidelines/nierenzellkarzinom-hypernephrom/@@view/html/index.html EU Launch Territories: Germany, the U.K., Austria, the Netherlands and Sweden $2M milestone payment Nov 18 ~$200M Market (2017); 50% of sa

  32. Slide 32: Ficlatuzumab, CAN017 (AV-203) and AV-380

    Slide 32: Ficlatuzumab, CAN017 (AV-203) and AV-380

    Ficlatuzumab SCCHN: Randomized Phase 2 Trial Ongoing (Ficlatuzumab + Erbitux vs. Ficlatuzumab) Pancreatic Cancer: Phase 1/2 Trial Ongoing (Ficlatuzumab + Nab-paclitaxel + Gemcitabine) AML: Phase 1b/2 Trial Ongoing (Ficlatuzumab + High Dose Cytarabine (HiDAC) COM and other IP to at least 2027 CAN017

  33. Slide 33: Financial Highlights

    Slide 33: Financial Highlights

    Financial Highlights $20.4M in cash, cash equivalents, and investments as of 3Q 2018 Additional $8.4 million raised through ATM sales agreement in 4Q 2018 $2M reimbursement milestone from EUSA for Germany incurred in Nov 2018 Funds planned operations into 3Q 2019* Restructured debt provides +cash fl

  34. Slide 34: AVEO Overview February 2019

    Slide 34: AVEO Overview February 2019

    AVEO Overview February 2019

Source: SEC EDGAR · 8-K filed Feb 15, 2019

More decks from AVEO Pharmaceuticals Inc